pascale grosclaude

Dr. pascale grosclaude

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet
Verified
Journal Article
Open access
CAClaudia Allemani
Claudia Allemani
TMTomohiro Matsuda
Tomohiro Matsuda
VCVeronica Di Carlo
Veronica Di Carlo
RHRhea Harewood
Rhea Harewood
MMMelissa Matz
Melissa Matz
CLC Lewis
C Lewis
In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark). The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation.

1 December 2003 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MSM. Sant
M. Sant
TAT. Aareleid
T. Aareleid
FBF. Berrino
F. Berrino
MLM. Bielska Lasota
M. Bielska Lasota
PCP. M. Carli
P. M. Carli
DLD. Lisi
D. Lisi
1Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; 2Institute of Experimental and Clinical Medicine and Estonian Cancer Registry, Tallinn,

1 June 2008 in Revue D'Épidémiologie Et de Santé Publique
Verified
Journal Article
Closed access
ABAurelien Belot
Aurelien Belot
PGpascale grosclaude
pascale grosclaude
NBN. Bossard
N. Bossard
EJE. Jougla
E. Jougla
EBE. Benhamou
E. Benhamou
MVM. Velten
M. Velten

1 August 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
RCRiccardo Capocaccia
Riccardo Capocaccia
LBLaura Botta
Laura Botta
SMSandra Mallone
Sandra Mallone
RARoberta De Angelis
Roberta De Angelis
EBEllen Benhamou
Ellen Benhamou

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
María-José SánchezMaría-José Sánchez
María-José Sánchez
LALesley Ann Anderson
Lesley Ann Anderson
Daniela PierannunzioDaniela Pierannunzio
Daniela Pierannunzio
ROR. Otter
R. Otter

27 April 2012 in Journal of Epidemiology and Community Health
Verified
Journal Article
Open access
PDF file
CPCarole Pornet
Carole Pornet
Cyrille DelpierreCyrille Delpierre
Cyrille Delpierre
ODOlivier Dejardin
Olivier Dejardin
PGpascale grosclaude
pascale grosclaude
LLLudivine Launay
Ludivine Launay
GLGuy Launoy
Guy Launoy
Background Studying social disparities in health implies the ability to measure them accurately, to compare them between different areas or countries and to follow trends over time. This study proposes a method for constructing a French European deprivation index, which will be replicable in several European countries and is related to an individual deprivation indicator constructed from a European survey specifically designed to study deprivation. Methods and Results Using individual data from the European Union Statistics on Income and Living Conditions survey, goods/services indicated by individuals as being fundamental needs, the lack of which reflect deprivation, were selected. From this definition, which is specific to a cultural context, an individual deprivation indicator was constructed by selecting fundamental needs associated both with objective and subjective poverty. Next, the authors selected among variables available both in the European Union Statistics on Income and Living Conditions survey and French national census those best reflecting individual experience of deprivation using multivariate logistic regression. An ecological measure of deprivation was provided for all the smallest French geographical units. Preliminary validation showed a higher association between the French European Deprivation Index (EDI) score and both income and education than the Townsend index, partly ensuring its ability to measure individual socioeconomic status. Conclusion This index, which is specific to a particular cultural and social policy context, could be replicated in 25 other European countries, thereby allowing European comparisons. EDI could also be reproducible over time. EDI could prove to be a relevant tool in evidence-based policy-making for measuring and reducing social disparities in health issues and even outside the medical domain.